This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
847
Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
Unnamed facility
Gangwon-do, South Korea
Percentage of Patients Reporting Adverse Events
An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Time frame: Up to 10 Months
Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale
Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.
Time frame: Baseline, 2 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.